Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Jumps 6.8 Percent on Positive Nasdaq Outcome

NEW YORK (GenomeWeb News) – Shares in Ciphergen Biosystems were up 6.76 percent, or $.09, at $1.42 in mid-afternoon trading after the company said its shares have regained compliance with the Nasdaq exchange.
 
As GenomeWeb News reported this morning, Ciphergen said the exchange has allowed it to move its shares to its Capital Market from the National Market.
 
To remain listed on the Capital Market Ciphergen must, among other things, have a market capitalization greater than $35 million, the company said in a Securities and Exchange Commission filing today. Ciphergen’s market cap is currently around $48 million.
 
Ciphergen in July said that the Nasdaq notified it that it is subject to delisting from the National Market because its market cap had fallen below $50 million for 10 consecutive business days.
 
Its stock will trade on the Capital Market on Aug. 28 under the ticker symbol CIPH.
 
“By transferring from the Nasdaq Global Market to the Nasdaq Capital Market, Ciphergen satisfies the listing requirements” for the exchange, Ciphergen said in statement.
 
Ciphergen’s “continued listing on the Nasdaq Capital Market is subject to its successful completion of an application and review process,” the company said in the SEC filing.
The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.